English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew study shows CAR T cells expressing RN7SL1 can activate the body’s natural immune cells against difficult-to-treat cancers
Tag: Oncology
Two Studies Seek to Go Beyond the GIST of Intestinal Tract Cancer
UC San Diego researchers identify the mutational drivers for gastrointestinal stroma tumors in the stomach and find a potential drug to treat a subset of GIST tumors afflicting the young.
Sylvester Comprehensive Cancer Center Researchers Awarded Major Multi-Center Grant to Study Uveal Melanoma
Researchers at the Sylvester Comprehensive Cancer Center in the University of Miami Miller School of Medicine, Moffitt Cancer Center and the University of Florida Health Cancer Center received a five-year, $3.95 million NIH grant to study how uveal melanoma spreads to the liver. This work was previously supported by two Florida State Team Science Awards, which provided early-stage funding to help the team progress to the larger NIH grant.
Yale Cancer Center Perspective Highlights New Advances for NSCLC
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical research areas to help influence how NSCLC will be managed over the coming decade.
Cancer treatment and research ‘brain gain’
Cancer patients will benefit from world-class research and new treatments with the appointment of three globally-lauded scientists to the University of Adelaide’s South Australian immunoGENomics Cancer Institute (SAiGENCI).
Cancer treatment and research ‘brain gain’
Cancer patients will benefit from world-class research and new treatments with the appointment of three globally-lauded scientists to the University of Adelaide’s South Australian immunoGENomics Cancer Institute (SAiGENCI).
Jersey Shore University Medical Center Now Offers Elite Regional Expertise in Orthopedic Oncology
The care of cancer (sarcomas) of the bones and soft tissues requires the expertise of a highly specialized team. Jersey Shore University Medical Center is among two of the elite Hackensack Meridian Health locations in New Jersey to offer clinical expertise in the field of orthopedic oncology.
FAU Nursing Faculty Member Receives NIH K01 Grant for Breast Cancer Research
Tarsha Jones, Ph.D., principal investigator and an assistant professor of nursing at FAU’s Christine E. Lynn College of Nursing, has received the National Institute of Health (NIH) K01 Career Development Award, a five-year, $772,525 award for a project titled, “Decision Support for Multigene Panel Testing and Family Risk Communication among Racially/Ethnically Diverse Young Breast Cancer Survivors.”
John Theurer Cancer Center Selected as One of Four Beneficiaries at the 2021 Breeders Crown Charity Challenge
Hackensack Meridian John Theurer Cancer Center has been selected as one of four beneficiaries of the 2021 Breeders Crown Charity Challenge, presented by the Libfeld/Katz Breeding Partnership.
Fred Hutchinson Cancer Research Center, Seatle Children’s and UW Medicine Lay Groundwork for Historic Cancer Partnership
SEATTLE — July 13, 2021 — Fred Hutchinson Cancer Research Center, UW Medicine, Seattle Cancer Care Alliance and Seattle Children’s today announced plans to explore restructuring their longtime relationship to accelerate a d mission of advancing diagnosis, treatment and pioneering of cures for cancer and other diseases.If finalized and approved, the proposed restructure would establish an adult-focused oncology program and, separately, a pediatric oncology program.
NCCN Maintains Qualification as CMS-Approved Provider-Led Entity for the Development of Imaging Appropriate Use Criteria
NCCN, an alliance of 31 leading cancer centers, has again qualified as a provider-led entity (PLE) for the Medicare Appropriate Use Criteria (AUC) Program by Centers for Medicare & Medicaid Services (CMS), the nation’s largest health payer.
CAP Releases Updates to Cancer Protocols, Essential for Cancer Reporting and Patient Care
The College of American Pathologists (CAP) released updates to the CAP Cancer Protocols, clinical guidance for reporting pathologic features in the treatment of cancer patients.
Researchers engineer ‘natural killer’ cells that attack and destroy malignant tumour cells but leave the rest alone
Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumours.
Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
Blood cancer patients with COVID-19 fare better with convalescent plasma
A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus. The therapy involves transfusing plasma — the pale yellow liquid in blood that is rich in antibodies — from people who have recovered from COVID-19 into patients who have leukemia, lymphoma or other blood cancers and are hospitalized with the viral infection.
Yale Cancer Center Study Reveals New Pathway for Brain Tumor Therapy
In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.
Surgeon and reproductive scientist Patricia Kilroy Donahoe, MD, FACS, named recipient of 2021 Jacobson Innovation Award
One of the world’s most influential reproductive scientists, Patricia Kilroy Donahoe, MD, FACS, will receive the 2021 Jacobson Innovation Award of the American College of Surgeons (ACS) during a virtual event to be held in her honor this evening.
Yale Cancer Center Study Shows Novel Test Can Detect New and Recurrent Bladder Cancer
A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.
John Theurer Cancer Center investigators report new findings at American Society of Clinical Oncology 2021 Annual Meeting
Innovative research refines the treatment of patients with advanced cancers and the use of immunotherapy
Inflammation and Procalcitonin Predict Success, or Not, of Lung Cancer Treatment
In patients with non-small cell Lung Cancer (NSCLC), the presence of either high chronic inflammation, or procalcitonin levels in the blood as a response to bacterial infection, both predict a poor response to treatment with immune checkpoint blockade.
Rare Case of Lactic Acidosis Associated with Small Lymphocytic Lymphoma (SLL) in Elderly Man Published in Journal of Cancer Research and Oncobiology
A team of researchers from Hackensack Meridian Jersey Shore University Medical Center and the Cleveland Clinic, led by Professor of Medicine and Nephrologist Sushil K. Mehandru, M.D., authored a new report.
Yale Cancer Center Study Shows Cognitive Impairment for Survivors of Many Pediatric Cancers
In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income. The results were published online today in the Journal of Clinical Oncology (JCO).
Researchers Identify New Role for Immune-Boosting Protein “STING” in Treatment of Head and Neck Cancer
In a study by Yale Cancer Center, researchers report on the discovery of a new role for STimulator of INterferon Genes or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumor DNA damage response.
Researchers Discover Common Mechanism Causing Autoimmune Disease and Blood Cancers
In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
Atlantic Health System Physicians Co-Author 5 Studies, Presented at American Association for Cancer Research (AACR) Annual Meeting
Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.
NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg).
Researchers Identify Genes Behind Uterine Leiomyosarcoma Which May Be Treated Using Precision Medicine
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
CAP Opens PD-L1 Lung Tumor Testing Guideline for Public Comment
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Yale Researchers Identify Tumor Reactive Immune-Cells to help fight against Advanced Melanoma
According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma, a deadly form of skin cancer. The findings were published today in the Journal of Experimental Medicine.
Chênevert Family Brain Tumor Center Launched at Yale
Yale School of Medicine announces a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Chênevert Family Brain Tumor Center will be a leading center in Neuro-Oncology research worldwide, bringing ground-breaking solutions and hope to patients with brain tumors.
Study Shows New Treatment Pathway to Prevent and Treat Endometrial Cancer Recurrence
In a new study led by Yale Cancer Center, researchers demonstrate sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer.
Maryam Lustberg Named Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as an Associate Professor of Medicine (Medical Oncology).
Model helps predict which patients will benefit most from PSMA PET scan
A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.
Mount Sinai Health System Launches Center for Light and Health Research
The clinical research conducted through the Center will investigate how to use light to improve people’s lives by stabilizing their circadian rhythms, the natural internal clock that regulates the body’s sleep-wake cycle. Researchers will study how light, either from daylight or electric indoor light, affects circadian rhythms in various populations, from the very young to the very old, including patients with COVID-19, cancer, Alzheimer’s disease, depression, and other illnesses. The goal is to help abate symptoms and improve their sleep, mental health, and cognition.
Researchers Discover Mechanism to Overcome Drug-Resistance in B-Cell Acute Lymphoblastic Leukemia
In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences.
Dana-Farber to hold a discussion for cancer patients and survivors about the Covid-19 vaccine
Dana-Farber Cancer Institute is having a virtual discussion for cancer patients and survivors about the Covid-19 vaccine on January 27, 2020 at 5 pm.
Dr. Rachel Greenup Appointed Chief of Breast Surgical Oncology at Yale
Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery (Oncology) and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine. In her new role, Dr. Greenup will provide breast surgical oncology leadership across the Smilow Cancer Hospital Network and Care Centers.
Strange colon discovery explains racial disparities in colorectal cancer
The colons of African-Americans and people of European descent age differently, new research reveals, helping explain racial disparities in colorectal cancer – the cancer that killed beloved “Black Panther” star Chadwick Boseman.
Dynamic, personalized treatment approach may improve outcomes in gastroesophageal cancers
A phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls.
Personalizing Cancer Care with Improved Tumor Models
While decades of research have resulted in substantial improvements in surviving cancer, a key challenge remains in identifying new drugs that improve outcomes for patients. In APL Bioengineering, researchers suggest a major hurdle is the paucity of models for cancer research that accurately represent patient tumors. They provide a perspective on strategies using models from individual patients and where the field needs to go in terms of research in animal systems and in culture systems.
Embracing Complexity
Ben Ferguson joins the UNM Comprehensive Cancer Center as surgical oncologist. It was the complexity of cancer care that drew him to the specialty and the resources of a comprehensive cancer center that drew him to UNM.
Yale study leads to FDA approval of drug to treat non-small cell lung cancer
Based on results of a clinical trial led by Yale Cancer Center researchers, the U.S. Food and Drug Administration has approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations, which occurs in about 10 percent of patients.
Roy S. Herbst, MD, PhD, Receives 2020 ACCC Clinical Research Award
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.
Dr. Stephanie Halene Appointed Chief of Hematology at Yale Cancer Center and Smilow Cancer Hospital
Following an extensive national search, Stephanie Halene, MD, PhD, has been appointed Chief of Hematology at Yale Cancer Center, Smilow Cancer Hospital and the Yale School of Medicine Department of Internal Medicine.
Henry Ford Cancer Institute and United Outstanding Physicians Partner to Enhance Care, Experience for Cancer Patients
Henry Ford Cancer Institute and United Outstanding Physicians (UOP), a physician organization comprising nearly 1,000 independent private practice physicians across Southeast Michigan, have come together to enhance cancer care and make navigating the cancer journey easier for their patients.
Yale Cancer Center Study Shows Caplacizumab Not Cost Effective for Rare Blood Disorder
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.
Novel antibody-drug conjugate shows promising early results in rare blood cancer
A phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center found IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm.
Rutgers Researcher Receives $400K Grant to Reduce Racial Health Disparities in Cancer Care
Anita Kinney, professor at the Rutgers School of Public Health and associate director for Population Science and Community Outreach at Rutgers Cancer Institute of New Jersey, is one of ten recipients across the nation of an American Cancer Society and Pfizer community grant of $399,892 to support investigation into reducing racial health disparities in cancer care through precision oncology and immunotherapy.
First Report Card on Biosimilars in Oncology
SUMMARY Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor at the George Washington University…
Yale Cancer Center Study Shows Regional Variation in Genomic Testing for Men with Prostate Cancer
In a new study by Yale Cancer Center, researchers found substantial regional variation in use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies.